PFE Jun 2024 70.000 call
| Previous close | 0.0300 |
| Open | 0.0300 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 70.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0300 - 0.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.89k |
Yahoo FinanceAWS expands big pharma partnerships in manufacturing, AI, and R&D
Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.
GlobeNewswireArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrog
Insider Monkey12 Very High Yield Dividend Stocks With Upside Potential
In this article, we discuss 12 very high yield dividend stocks with upside potential. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Very High Yield Dividend Stocks With Upside Potential. Many investors are drawn to dividend investing for various reasons, but among […]
